Form 8-K - 3rd Quarter 2006 Earnings Release
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): August 11, 2006
AEOLUS
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or
other jurisdiction of incorporation)
0-50481 56-1953785
(Commission
File Number)
(IRS
Employer Identification No.)
23811
Inverness Place
Laguna
Niguel, California 92677
(Address
of Principal Executive Offices, Including Zip Code)
949-481-9825
(Registrant’s
Telephone Number, Including Area Code)
__________________
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
£ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
£ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
| |
£
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
| £ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
2.02 Results
of Operations and Financial Condition.
On
August
11, 2006, Aeolus Pharmaceuticals, Inc. issued an earnings release to announce
its earnings for the three months and nine months ended June 30, 2006.
The
earnings release is included in this report as Exhibit 99.1.
The
information in Exhibit 99.1 is being furnished and shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that
Section. The information in Exhibit 99.1 shall not be deemed incorporated by
reference into any registration statement or other document filed with the
Securities and Exchange Commission (the “SEC”), regardless of any general
incorporation language in such filing.
Item
9.01. Financial Statements and Exhibits.
|
Exhibit
#
|
|
Description
|
|
99.1
|
|
Press
release dated August 11, 2006
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this Report to be signed on its behalf by the undersigned hereunto
duly authorized.
AEOLUS
PHARMACEUTICALS, INC.
Date:
August 11, 2006
/s/
Michael P. McManus___________________
Michael
P. McManus
Chief
Financial Officer, Treasurer and Secretary